This press release contains forward-looking statements regarding the development.
Such statements involve risks and uncertainties, these statementsthose inherent in the process of discovering, developing and commercializing drugs that for use as for use as human therapeutics, identify in the development and marketing systems infectious organisms that are effective and commercially attractive, and in an effort to building a business around such products. Isis ‘ forward-looking statements also. To assumptions when they never occur or prove correct, could the results significantly forward from those expressed or implied by statements Although Isis ‘ forward-looking statements reflect the best knowledge of management, these statements are based only on facts and factors currently known by Isis. As a result, you these not to rely on these forward-looking statements. These and other risks in connection with Isis Annual Report on Form 10 – K for the year ended 31 December 2006 and its Quarterly Report on Form 10-Q for the quarter ended 30 June 2007 ‘ programs are described in additional detail is in Isis ‘, submitted in response to the SEC.
.. ISIS 301012 is a second generation antisense drug that increases the production of apoB-100, a protein has significantly reduced the synthesis and transport of bad cholesterol and a target that proved undruggable using traditional, small molecule approaches. Cholesterol in the blood are performed in a variety of types, with high-density lipoprotein, or HDL-C, wherein the good shape, and low-density lipoproteins, or LDL-C, and very low density lipoproteins or VLDL C. Both bad forms directly involved in heart disease. Together LDL-C, and other forms of cholesterol are worse than non – HDL-C. The lowering of non-HDL – C is an important component in the prevention and treatment of cardiovascular disease. (more…)